Nursing diagnoses in patients with immune-bullous dermatosis

ABSTRACT Objective: identify nursing diagnoses in patients with immune-bullous dermatosis. Method: a quantitative and descriptive research, carried out in three institutions located in Rio de Janeiro and Mato Grosso do Sul, Brazil, using the Client Assessment Protocol in Dermatology during a nursing consultation. Simple descriptive statistics was used for data analysis. Results: 14 subjects participated in the study, nine with a diagnosis of pemphigus vulgaris, pemphigus two and three of bullous pemphigoid. The age ranged between 27 and 82 years, predominantly females (11). 14 nursing diagnoses were discussed and identified from a clinical rationale in all study participants, representing the most common human responses in this sample. The application of the Assessment Protocol in Dermatology facilitated the comprehensive assessment, in addition to providing the identification of diagnostics according to the North American Nursing Diagnosis Association International. Conclusion: the nursing diagnoses presented confirm the necessity of interdisciplinary work during the care for this clientele. For better description of the phenomena related to the client in question, it is suggested the inclusion of two risk factors related in three diagnoses of this taxonomy. It is worth noting the contribution of the findings for the care, education and research in nursing in dermatology

A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas

Background: Prolactinoma, the most common pituitary adenoma, is usually treated with dopamine agonist (DA) therapy like cabergoline. Surgery is second-line therapy, and radiotherapy is used if surgical treatment fails or in relapsing macroprolactinoma. Objective: This study aimed to provide economic evidence for the management of prolactinoma in Italy, using a cost-of-illness and cost-utility analysis that considered various treatment options, including cabergoline, bromocriptine, temozolomide, radiation therapy, and surgical strategies. Methods: The researchers conducted a systematic literature review for each research question on scientific databases and surveyed a panel of experts for each therapeutic procedure’s specific drivers that contributed to its total cost. Results: The average cost of the first year of treatment was €2,558.91 and €3,287.40 for subjects with microprolactinoma and macroprolactinoma, respectively. Follow-up costs from the second to the fifth year after initial treatment were €798.13 and €1,084.59 per year in both groups. Cabergoline had an adequate cost-utility profile, with an incremental cost-effectiveness ratio (ICER) of €3,201.15 compared to bromocriptine, based on a willingness-to-pay of €40,000 per quality-adjusted life year (QALY) in the reference economy. Endoscopic surgery was more cost-effective than cabergoline, with an ICER of €44,846.64. Considering a willingness-to-pay of €40,000/QALY, the baseline findings show cabergoline to have high cost utility and endoscopic surgery just a tad above that. Conclusions: Due to the favorable cost-utility profile and safety of surgical treatment, pituitary surgery should be considered more frequently as the initial therapeutic approach. This management choice could lead to better outcomes and an appropriate allocation of healthcare resources

(Clinical) trial and error in diabetic nephropathy

Patients with diabetes and nephropathy face a high risk of end-stage renal disease (ESRD) and cardiovascular disease. Trials in the past decades of nephrology research have shown the importance of lowering glucose, blood pressure, and albuminuria as a mean to lower renal and cardiovascular risk in these patients. However, despite the promising and successful results from RAAS inhibition with angiotensin receptor blockers in combination with tight glycemic and blood pressure control, many patients with diabetes and nephropathy are left with a high residual risk and still progress to ESRD. The high residual risk highlights the urgent need for additional therapies. This chapter reviews the clinical trial landscape in diabetic nephropathy and draws lessons for future clinical trials in this area.In order to improve outcome of patients with diabetic nephropathy, novel drugs have been tested in the last decades. After numerous large and expensive trials, unfortunately only a few interventions have been shown to reduce the risk of ESRD. One of the potential explanations why many of the conducted trials failed to prove ultimate efficacy is that all interventions focused on the effect of the drug in the overall population without taking into account how the individual patient responded to the drug. In the past trials, individual patients showed a large variation in drug response: some patients benefitted, and others did not or even experienced an increased risk. Because of this variation, no benefit could be detected in the overall population. The drug response variation may thus play a much bigger and more important role than originally anticipated in clinical trial design.The important lesson learned from a decade of clinical trial failures in nephrology is that more emphasis should be placed on the individual and how the individual responses to the drug rather than evaluating drug effects on a population level. This personalized medicine concept should be integrated in the design of future clinical trials as there are still promising therapies at the horizon for diabetic nephropathy and their potential efficacy should be tested in an appropriate fashion

A randomized open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC : the European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR trial

Introduction Receptor activator of NF-kB ligand stimulates NF-kB–dependent cell signaling and acts as the primary signal for bone resorption. Retrospective analysis of a large trial comparing denosumab versus zoledronic acid in bone metastatic solid tumors suggested significant overall survival (OS) advantage for patients with lung cancer with denosumab (p = 0.01). The randomized open-label phase III SPLENDOUR trial was designed to evaluate whether the addition of denosumab to standard first-line platinum-based doublet chemotherapy improved OS in advanced NSCLC. Methods Patients with stage IV NSCLC were randomized in a 1:1 ratio to either chemotherapy with or without denosumab (120 mg every 3–4 wks), stratified by the presence of bone metastases (at diagnosis), Eastern Cooperative Oncology Group performance status, histology, and region. To detect an OS increase from 9 to 11.25 months (hazard ratio [HR] = 0.80), 847 OS events were required. The trial closed prematurely owing to decreasing accrual rate. Results A total of 514 patients were randomized, with 509 receiving one or more doses of the assigned treatment (chemotherapy: 252, chemotherapy-denosumab: 257). The median age was 66.1 years, 71% were men, and 59% were former smokers. Bone metastases were identified in 275 patients (53%). Median OS (95% confidence interval [CI]) was 8.7 (7.6–11.0) months in the control arm versus 8.2 (7.5–10.4) months in the chemotherapy-denosumab arm (HR = 0.96; 95% CI: 0.78–1.19; one-sided p = 0.36). For patients with bone metastasis, HR was 1.02 (95% CI: 0.77–1.35), whereas for those without, HR was 0.90 (95% CI: 0.66–1.23). Adverse events grade 3 or greater were observed in 40.9%, 5.2%, 8.7% versus 45.5%, 10.9%, 10.5% of patients. Conditional power for OS benefit was less than or equal to 10%. Conclusions Denosumab was well-tolerated without unexpected safety concerns. There was no OS improvement for denosumab when added to chemotherapy in the intention-to-treat population and the subgroups with and without bone metastases. Our data do not provide evidence of a clinical benefit for denosumab in patients with NSCLC without bone metastases

Epidemiology of surgery associated acute kidney injury (EPIS-AKI) : a prospective international observational multi-center clinical study

The incidence, patient features, risk factors and outcomes of surgery-associated postoperative acute kidney injury (PO-AKI) across different countries and health care systems is unclear. We conducted an international prospective, observational, multi-center study in 30 countries in patients undergoing major surgery (> 2-h duration and postoperative intensive care unit (ICU) or high dependency unit admission). The primary endpoint was the occurrence of PO-AKI within 72 h of surgery defined by the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Secondary endpoints included PO-AKI severity and duration, use of renal replacement therapy (RRT), mortality, and ICU and hospital length of stay. We studied 10,568 patients and 1945 (18.4%) developed PO-AKI (1236 (63.5%) KDIGO stage 1500 (25.7%) KDIGO stage 2209 (10.7%) KDIGO stage 3). In 33.8% PO-AKI was persistent, and 170/1945 (8.7%) of patients with PO-AKI received RRT in the ICU. Patients with PO-AKI had greater ICU (6.3% vs. 0.7%) and hospital (8.6% vs. 1.4%) mortality, and longer ICU (median 2 (Q1-Q3, 1-3) days vs. 3 (Q1-Q3, 1-6) days) and hospital length of stay (median 14 (Q1-Q3, 9-24) days vs. 10 (Q1-Q3, 7-17) days). Risk factors for PO-AKI included older age, comorbidities (hypertension, diabetes, chronic kidney disease), type, duration and urgency of surgery as well as intraoperative vasopressors, and aminoglycosides administration. In a comprehensive multinational study, approximately one in five patients develop PO-AKI after major surgery. Increasing severity of PO-AKI is associated with a progressive increase in adverse outcomes. Our findings indicate that PO-AKI represents a significant burden for health care worldwide

Ancestral association between HLA and HFE H63D and C282Y gene mutations from northwest Colombia

A significant association between HFE gene mutations and the HLA-A*03-B*07 and HLA-A*29-B*44 haplotypes has been reported in the Spanish population. It has been proposed that these mutations are probably connected with Celtic and North African ancestry, respectively. We aimed to find the possible ancestral association between HLA alleles and haplotypes associated with the HFE gene (C282Y and H63D) mutations in 214 subjects from Antioquia, Colombia. These were 18 individuals with presumed hereditary hemochromatosis (“HH”) and 196 controls. The HLA-B*07 allele was in linkage disequilibrium (LD) with C282Y, while HLA-A*23, A*29, HLA-B*44, and B*49 were in LD with H63D. Altogether, our results show that, although the H63D mutation is more common in the Antioquia population, it is not associated with any particular HLA haplotype, whereas the C282Y mutation is associated with HLA-A*03-B*07, this supporting a northern Spaniard ancestry

Numerical investigation of the fire resistance of protected cross-laminated timber floor panels

Several experimental investigations have been performed on timber elements to determine their fire resistance. However, the numerical modelling is nowadays an effective and inexpensive alternative method to investigate the behaviour of timber structures in fire conditions. Once validated on experimental data, finite element models can be used to understand more in detail the experimental behaviour, and then employed to carry out parametric studies where geometrical, mechanical and thermal properties are varied. After an extensive discussion on the state-of-the-art in numerical modelling of timber members and connections in fire conditions, the paper presents a two-dimensional model implemented in ABAQUS software package to simulate fire tests of cross-laminated timber (XLAM) floor panels protected with different cladding systems. The temperature distribution within the XLAM cross-section and the fire resistance of panels loaded out-of-plane were predicted through thermal and thermo-mechanical analyses, respectively. Since the stiffness and strength degradation of wood with temperature is still subject of research, a parametric study with different degradation laws was carried out. Numerical predictions were compared with experimental results showing acceptable accuracy, particularly when the degradation laws of the EN 1995-1-2 were used. The comparisons also show the need to model correctly the failure of the protective cladding for an accurate prediction of the thermal behaviour

"Finite element modelling of cross-laminated timber floors exposed to fire"

The paper presents a finite element model implemented in Abaqus software package to investigate the thermal and structural performance of protected and unprotected cross-laminated timber (Xlam) floor panels loaded out-of-plane and exposed to standard fire. The temperature-dependent relationships for wood properties proposed by the European code for fire design of timber structures were adopted in the modelling. The ‘concrete damaged plasticity’ model readily available in Abaqus was used to describe the non-linear mechanical behaviour of timber. The falling-off of the protective layer was simulated numerically as observed in the experiments. The numerical results in terms of temperature and stress distributions along the depth of a Xlam panel highlight the effect of the protective layer on heat transfer and consequently on stresses. By comparison with experimental results, an accurate prediction of the fire resistance of Xlam floor panels was attained